





## Robocath launches new robotic platform R-One+

Rouen, France, May 16, 2023 – Robocath, a company that designs, develops and commercializes smart robotic solutions for the treatment of cardiovascular diseases, today announces the launch of its latest robotic platform - the R-One+. Robocath will showcase this new solution during the upcoming international [EuroPCR conference](#) in Paris (France), from May 16 to 19, at the company's booth (M19, second floor). The R-One+ platform will also be presented in more detail during a dedicated session 'Robotic PCI: real-life experience with a new robotic platform', on May 16, room 252B, between 1:45pm and 2:45pm (CEST).



The R-One+ robotic solution allows the interventional cardiologist to perform coronary angioplasties by controlling the devices using an integrated control command unit located in the cathlab or in the control room. This creates two main benefits: firstly, the system protects the cardiologist and the medical team against radiation-induced injuries, and secondly it makes the PCI procedure easier and safer. Thanks to R-One+, cardiologists can perform enhanced hand gestures with even greater precision and in more comfortable working conditions, all of which benefits the patient.

“For the first time, I was able to perform several robotic angioplasties from the comfort of my chair in the control room, where I was completely shielded from X-rays and could



dispense with my lead apron. I also benefited from the excellent visibility on the radioscopes and hemodynamic monitoring screens. This new set-up has changed the way we organize our procedures and has given nursing staff the opportunity to develop new skills. This new approach has also enabled doctors to shift their focus back to their core activities and to perform procedures in complete safety and with millimeter precision. I'm excited to incorporate this new robotic technology into my day-to-day work. Without doubt, it opens up some new and extremely promising avenues for the treatment of cardiovascular diseases, especially in the case of long and complex procedures," said **Dr. Mohammed Nejjari, interventional cardiologist at the Centre Cardiologique du Nord (CCN) in Saint-Denis, France.**

"R-One+ makes it extremely easy to position devices with millimeter precision. It's also much more comfortable to operate using robotic technology, and, as the principal operator, I am completely protected from radiation. I firmly believe that robotics has a major role to play in the transformation of interventional cardiology and the use of this technology will mark a new chapter in the history of our field," said **Prof. Michael Haude, interventional cardiologist at the Lukaskrankenhaus hospital in Neuss, Germany.**

"The launch of R-One+ shows what our company is all about — that is, listening to our users' needs and fostering exceptional partnerships between our different units in order to produce the best possible results for physicians. I would like to thank the medical community for giving their time so willingly and for their excellent advice. I would also like to thank all our staff who have worked so hard to launch this new robotic platform and, in doing so, taken us one step further on our roadmap to greater commercial success," said **Lucien Goffart, CEO of Robocath.**

"Robotic technology is digitizing endovascular medicine. I'm delighted that we are now launching R-One+; this solution marks a major step forward in the digital transformation of the cathlab as we continue to work towards our goal of ensuring better care for patients and better protection for medical staff," said **Philippe Bencteux, president and founder of Robocath.**

## ROBOCATH AT EUROPCR 2023

Attendees at EuroPCR 2023 will be able to:

- Enjoy a demonstration of the R-One+ robotic platform and test out the system at Robocath's booth (M19) on the second floor. There will also be the opportunity to record this test-run thanks to a new partnership with Medinbox ([www.medinbox.com](http://www.medinbox.com))
- Find out all about the new R-One+ platform during the dedicated session '*Robotic PCI: real-life experience with a new robotic platform*', taking place between 1:45pm and 2:45pm (CEST), on May 16, in room 252B. The talk will be given by Dr. Jean Fajadet and Prof. Stefan Verheye and will include two case studies featuring the robotic technology, from Prof. Michael Haude of the Lukaskrankenhaus hospital in Neuss, Germany, and Dr. Mohammed Nejjari of the Centre Cardiologique du Nord (CCN) in Saint-Denis, France



## ABOUT ROBOCATH

Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes smart robotic solutions to treat cardiovascular diseases. As an active player in the digital evolution of the medical industry, its smart connected solutions aim to enhance hand gestures and make medical procedures safer.

Robocath develops robotic solutions which integrate a unique bionic technology that optimizes the safety of robotic-assisted coronary angioplasty. This medical procedure consists of revascularizing the cardiac muscle by inserting one or more implants (stents) into the arteries that supply it with blood. Every 30 seconds, somewhere in the world, this type of procedure is performed. Robocath's robotic solutions are designed to operate with precision and perform accurate movements, creating better interventional conditions. Thanks to their open architecture, they are all compatible with market-leading devices and cathlabs.

The company received the CE marking for R-One™, its first robotic solution, in 2019. In a prospective, multicenter, non-randomized, single-arm clinical trial, R-One demonstrated safety and efficacy as it achieved more than 95% technical procedure success with no MACE (major adverse cardiovascular events). Currently R-One is used in Europe, Africa and China.

By pursuing the development of smart digital solutions, Robocath aims to become a world leader in vascular robotics. Based in Rouen, France, Robocath has more than 70 employees.

[www.robocath.com](http://www.robocath.com)

## PRESS CONTACT

### ROBOCATH

Morgane Le Mellay  
[morgane.mellay@robocath.com](mailto:morgane.mellay@robocath.com)  
+33 (0)634 409 125

Emilie Chouinard / Saffiyah Khaliq  
[emilie@ala.associates](mailto:emilie@ala.associates) / [saffiyah@ala.associates](mailto:saffiyah@ala.associates)  
UK +44 1273 952 481  
US +1 203 724 5950